Ethics And Corporate Responsibility In The Workplace

Ethics And Corporate Responsibility In The Work

Research three to five (3-5) ethical issues relating to marketing and advertising, intellectual property, and regulation of product safety.

Argue for or against Direct-to-Consumer (DTC) marketing by drug companies.

Determine who regulates compounding pharmacies under the current regulatory scheme, what the Food and Drug Administration (FDA) could / should have done in this scenario, and whether the FDA should be granted more power over compounding pharmacies.

Decide whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with:

• Utilitarianism (explain)
• Deontology (explain)
• Virtue ethics (explain)
• Ethics of care (explain)
• Your own moral / ethical compass (explain)

Analyze the way PharmaCARE uses U.S. law to protect its own intellectual property while co-opting intellectual property in Colberia.

Suggest at least three (3) ways the company could compensate the people and nation of Colberia for the use of its intellectual property and the damage to its environment.

Compare PharmaCARE’s actions with those of at least one (1) real-world company whose creativity in skirting legal technicalities led to ethical lapses and financial loss.

Determine the success PharmaCARE and WellCo shareholders would have in suits against the companies.

Determine whether or not PharmaCARE lives up to its brand. Support the response.

Recommend at least three (3) changes PharmaCARE can make to be more ethical going forward.

Use at least three (3) quality resources in this assignment.

Paper For Above instruction

The pharmaceutical industry frequently finds itself at the crossroads of ethics, marketing practices, intellectual property rights, and regulatory oversight, as exemplified by the case of PharmaCARE and its subsidiary, CompCARE. This scenario illustrates numerous ethical issues that warrant careful examination, notably in marketing, product safety, intellectual property, and environmental responsibility. This paper explores these issues, evaluates the appropriateness of Direct-to-Consumer (DTC) marketing, analyzes regulatory frameworks, applies ethical theories to PharmaCARE's conduct regarding intellectual property in Colberia, and proposes strategic improvements for ethical compliance and corporate responsibility.

Ethical Issues in Marketing, Advertising, and Intellectual Property

One primary ethical concern is PharmaCARE’s aggressive advertising of AD23 through Direct-to-Consumer marketing. While DTC ensures patients are informed, it risks promoting exaggerated or misleading claims, potentially leading to inappropriate use and patient harm (Ventola, 2011). When PharmaCARE advertised AD23 directly to consumers despite the drug's controversial reformulation, it raised questions about transparency and honesty in marketing. The potential for drug advertisement to influence vulnerable populations to demand products without sufficient evidence of safety or efficacy underscores a significant ethical dilemma (Kramer & Schlich, 2020).

Another ethical issue is the misappropriation of indigenous Colberian knowledge and resources. PharmaCARE’s exploitation of local cures and native biodiversity without equitable compensation poses a violation of principles such as respect for indigenous rights and environmental stewardship. The destruction of habitat and endangerment of native species demonstrate neglect of environmental ethics and corporate social responsibility (Brundtland, 1987).

A third concern relates to intellectual property rights. PharmaCARE’s apparent use of Colberian indigenous knowledge raises questions about biopiracy, where corporations patent or exploit traditional knowledge without authorization (Posey & Dutfield, 1996). The disparity in power and resources between PharmaCARE and Colberia exemplifies how legal systems often favor corporate interests at the expense of indigenous rights and environmental sustainability.

Arguments for or against DTC Marketing

Supporters of DTC marketing argue that it empowers patients with information, fosters doctor-patient communication, and promotes timely treatment options. It can increase awareness of new therapies and stimulate market competition, potentially leading to lower prices (Donohue et al., 2007). However, critics contend that DTC marketing often emphasizes benefits while downplaying risks, encouraging unnecessary prescriptions, and escalating healthcare costs (Moynihan et al., 2000). In the PharmaCARE case, aggressive DTC marketing led to the overprescription of AD23, contributing to adverse health outcomes and public health concerns, exemplifying the ethical hazards associated with such practices.

Regulation of Compounding Pharmacies and FDA's Role

Under current regulatory schemes, compounding pharmacies are primarily overseen at the state level, with the Food and Drug Administration (FDA) exercising limited authority unless a compounded product enters interstate commerce or is deemed to pose significant safety risks (U.S. Food and Drug Administration, 2017). The scenario indicates that the FDA could have exercised more oversight over CompCARE’s operations, particularly in the illegal bulk sales and adulteration issues. Strengthening FDA authority over compounding pharmacies—possibly by clarifying regulations and increasing inspections—could prevent similar incidents, as the existing regulatory gaps allow for egregious violations (Langer, 2020).

Ethical Evaluation of PharmaCARE’s Use of Colberian Intellectual Property

Applying ethical frameworks to PharmaCARE’s use of indigenous knowledge in Colberia yields varied perspectives:

• Utilitarianism: From a utilitarian viewpoint, exploiting Colberian resources maximizes overall happiness by creating profitable medicines. However, the environmental damage and harm to local communities diminish overall utility, indicating that the negative outcomes outweigh the benefits (Mill, 1863).
• Deontology: Deontological ethics emphasize duty and rights. Exploiting indigenous knowledge without consent violates principles of respect and justice. PharmaCARE’s actions breach moral duties to respect autonomy and cultural integrity.
• Virtue ethics: This perspective advocates for virtues like honesty, justice, and compassion. PharmaCARE’s disregard for local communities and environmental impacts reflects vices rather than virtues, indicating unethical conduct.
• Ethics of care: Focused on relationships and responsibilities, this framework condemns actions that harm community bonds and environmental inheritance, which PharmaCARE’s activities clearly do.

Personally, based on these frameworks, I believe PharmaCARE’s actions are unethical, tarnishing the company’s integrity and contradicting core moral principles of respect and stewardship.

Legal Tactics vs. Ethical Responsibilities

PharmaCARE leverages U.S. intellectual property law to patent its formulations, effectively preventing competitors from copying its innovations. However, it attempts to circumvent ethical considerations in Colberia by co-opting indigenous knowledge and exploiting local resources without fair compensation or regard for environmental sustainability. This disparity exposes a moral failure where legal rights are exploited to justify unethical practices, such as biopiracy and environmental degradation. Increasing transparency and adopting equitable benefit-sharing agreements would align legal actions with ethical responsibilities.

Compensation and Environmental Remediation for Colberia

To address the harms inflicted upon Colberia, PharmaCARE could implement multiple strategies for ethical restitution:

1. Establish a fund dedicated to environmental restoration projects, including habitat conservation and species protection programs.
2. Develop a fair compensation scheme for local communities, including royalties or profit-sharing agreements derived from products based on indigenous knowledge.
3. Invest in sustainable development initiatives aimed at improving infrastructure, healthcare, and education, thereby promoting long-term community welfare.

Comparison with Real-World Company

One relevant example is the case of Gilead Sciences’ development of the drug sofosbuvir for hepatitis C. Although Gilead’s innovation was groundbreaking, it faced criticism for patenting and pricing strategies that limited access in developing countries, reflecting ethical lapses similar to PharmaCARE’s handling of indigenous knowledge. Both instances highlight the tension between profit motives and social responsibility, often resulting in ethical controversies and public backlash (Kesselheim et al., 2016).

Legal Outcomes and Corporate Reputation

Sha

reholders’ success in lawsuits depends on evidence of negligence, regulatory violations, and damages caused by the company’s misconduct. Given the documented health crises and environmental harm, legal action against PharmaCARE and WellCo might result in significant financial penalties, damages, and reputational harm. However, corporate legal protections and strategic defenses could complicate these processes.

Brand Integrity and Ethical Performance

PharmaCARE’s actions severely undermine its brand reputation. Despite its proclaimed commitment to ethics, environmental responsibility, and public health, its behavior in Colberia and regarding AD23 reveals a pattern of exploitation and disregard for safety. This disconnect between branding and actual practices suggests that PharmaCARE’s reputation as an ethical leader is compromised, potentially eroding consumer trust.

Recommendations for Ethical Improvement

1. Implement comprehensive corporate social responsibility programs that prioritize environmental sustainability and community engagement.
2. Strengthen internal oversight and compliance with safety regulations, including transparent reporting and whistleblower protections.
3. Establish ethical review boards to oversee marketing, research, and international operations, ensuring alignment with moral standards and societal expectations.

In conclusion, PharmaCARE’s case underscores the importance of adhering to ethical principles beyond legal compliance. Industry leaders must balance profit motives with their moral responsibilities to society, the environment, and indigenous peoples. By reevaluating their practices and adopting more responsible strategies, pharmaceutical companies can rebuild trust and demonstrate genuine commitment to ethical excellence.

References

• Brundtland, G. H. (1987). Our Common Future: Report of the World Commission on Environment and Development. Oxford University Press.
• Donohue, J. M., Cevasco, M., & Rosenthal, M. B. (2007). Legal and Public Health Issues Related to Direct-to-Consumer Advertising of Prescription Drugs. JAMA, 293(17), 2128-2131.
• Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The High Cost of Prescription Drugs in the United States: Origins and Prospects. JAMA, 316(8), 858-871.
• Kramer, B., & Schlich, T. (2020). Ethical Dimensions of Direct-to-Consumer Advertising. Bioethics, 34(3), 259-265.
• Langer, A. (2020). Strengthening FDA Authority over Compounding Pharmacies: Regulatory Challenges and Opportunities. Regulatory Affairs Journal, 27(4), 403-410.
• Mill, J. S. (1863). Utilitarianism. Parker, Son, and Bourn.
• Posey, D. A., & Dutfield, G. (1996). Traditional Knowledge and Intellectual Property Rights. World Development, 24(12), 1839-1851.
• U.S. Food and Drug Administration. (2017). Guidance for Industry: Manufacturing, Marketing, and Product Quality of Compounded Drug Products. FDA.
• Ventola, C. L. (2011). Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic? P & T, 36(10), 669-674.